This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech

Biotech Stock Mailbag: Threshold, Galena, CytRx

Biotech Stock Mailbag: Threshold, Galena, CytRx

Biotech columnist Adam Feuerstein answers readers' questions about health care.

08/22/14 - 08:48 AM EDT

Ampio: The Freezer Killed My Osteoarthritis Drug

  • Tickers in this article:
  • AMPE

Ampio Pharmaceuticals is blaming a mini Polar Vortex for blowing up a pivotal study of its osteoarthritis drug Ampion.

08/21/14 - 10:23 AM EDT

Epizyme First Look at Blood Cancer Drug Encourages

Epizyme First Look at Blood Cancer Drug Encourages

  • Tickers in this article:
  • EPZM

Epizyme's technology platform focuses on developing drugs to regulate a class of cancer-causing enzymes.

08/21/14 - 08:59 AM EDT

Galena CEO Fired Following Stock-Promotions Scandal

Galena CEO Fired Following Stock-Promotions Scandal

  • Tickers in this article:
  • GALE

Mark Ahn's forced exit from the troubled Galena follows an internal investigation by the board.

08/21/14 - 07:16 AM EDT

AstraZeneca Heart Drug Trial No Longer Subject of a Federal Probe

  • Tickers in this article:
  • AZN

AstraZeneca says the Department of Justice is ending its investigation into PLATO, a clinical trial with its heart drug Brilinta, and is not planning any further action.

08/19/14 - 01:02 PM EDT

Yes, Call It a Comeback: Amicus Fabry Drug Posts Big Study Win

Yes, Call It a Comeback: Amicus Fabry Drug Posts Big Study Win

Based on the positive study results, Amicus intends to seek European approval for migalastat early next year.

08/20/14 - 06:01 AM EDT

PDI CEO: Acquisition Puts us in the Diagnostic Sweet Spot

  • Tickers in this article:
  • PDII

PDI guided lower for the third quarter and full year, but CEO Nancy Lurker, says investors should look at what's in the pipeline at the company.

08/19/14 - 01:45 PM EDT

Why Jazz Pharmaceuticals (JAZZ) Stock Is Gaining Today

Why Jazz Pharmaceuticals (JAZZ) Stock Is Gaining Today

  • Tickers in this article:
  • JAZZ

Jazz Pharmaceuticals (JAZZ) shares are climbing after having coverage initiated with an 'overweight' rating and $190 price target at JPMorgan (JPM).

08/19/14 - 12:54 PM EDT

Top Swing Trade Ideas for Tuesday, August 19: Apple, Zynga, More

Top Swing Trade Ideas for Tuesday, August 19: Apple, Zynga, More

Apple, Amarin and Zynga are our big swing trades for today. So how should investors buy and sell?

08/19/14 - 10:17 AM EDT

Why Tekmira Pharmaceuticals (TKMR) Stock Is Spiking Today

Why Tekmira Pharmaceuticals (TKMR) Stock Is Spiking Today

  • Tickers in this article:
  • TKMR

Tekmira Pharmaceuticals (TKMR) shares are up double digits after having coverage initiated with an 'outperform' rating and $25 price target by analysts at Leerink.

08/18/14 - 01:29 PM EDT

Why Biogen Idec (BIIB) Stock Is Gaining Today

Why Biogen Idec (BIIB) Stock Is Gaining Today

  • Tickers in this article:
  • BIIB

Biogen Idec (BIIB) shares are climbing on Monday after the company's relapsing multiple sclerosis drug treatment, Plegridy, was approved by the FDA.

08/18/14 - 11:44 AM EDT

Why Spectrum Fell on Beleodaq Approval but Will Rocket on Melphalan Approval

Why Spectrum Fell on Beleodaq Approval but Will Rocket on Melphalan Approval

  • Tickers in this article:
  • SPPI

Spectrum's Beleodaq for Non-Hodgkin's lymphoma received FDA approval on July 3, but the stock then fell 26%. The same thing won't happen with Melphalan because sales numbers are already established.

08/18/14 - 07:47 AM EDT

50 Cent Teams With Intel in a Move To Take on Beats Electronics

Music mogul 50 Cent has taken his passion for quality sound into the high-end headphone market with his company, SMS Audio.

08/16/14 - 10:00 AM EDT

MannKind Snares Sanofi, Intercept Soars & Southwest's Mexico Move

MannKind signed a $925 million licensing pact with French drug maker Sanofi this week to sell its diabetes drug Afrezza.

08/15/14 - 09:41 AM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs